Brokers Issue Forecasts for Danaher's Q3 Earnings (NYSE:DHR)

Key Points

• Research analysts at Leerink Partnrs have lowered Danaher's Q3 2026 earnings per share (EPS) estimate from $1.84 to $1.83, while the consensus estimate for the full year is at $7.63 EPS.
• Danaher recently announced a quarterly dividend of $0.32 per share, to be paid on October 31st, with a dividend yield of 0.6% and a payout ratio of 27.23%.
• The stock has experienced a price target reduction from $230 to $220 by Bank of America, while other analysts have set targets as high as $275.

Danaher Corporation (NYSE:DHR - Free Report) - Research analysts at Leerink Partnrs decreased their Q3 2026 earnings per share (EPS) estimates for Danaher in a research report issued on Monday, October 13th. Leerink Partnrs analyst P. Souda now forecasts that the conglomerate will post earnings per share of $1.83 for the quarter, down from their previous forecast of $1.84. The consensus estimate for Danaher's current full-year earnings is $7.63 per share. Leerink Partnrs also issued estimates for Danaher's FY2026 earnings at $8.49 EPS.

DHR has been the topic of several other reports. Bank of America cut their price objective on Danaher from $230.00 to $220.00 and set a "buy" rating on the stock in a research report on Monday, September 22nd. Wall Street Zen raised Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Evercore ISI lifted their price objective on Danaher from $226.00 to $245.00 and gave the company an "outperform" rating in a research report on Tuesday, October 7th. Royal Bank Of Canada set a $241.00 price objective on Danaher in a research report on Tuesday, September 2nd. Finally, Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective on the stock in a research report on Friday, July 11th. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $244.60.

Danaher Stock Up 0.5%

NYSE DHR opened at $206.19 on Wednesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The stock has a market capitalization of $147.64 billion, a PE ratio of 43.87, a PEG ratio of 2.92 and a beta of 0.77. Danaher has a 1 year low of $171.00 and a 1 year high of $279.41. The business's 50-day moving average is $200.96 and its 200 day moving average is $197.13.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion for the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.Danaher's quarterly revenue was up 3.4% on a year-over-year basis. During the same period last year, the firm earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS.

Hedge Funds Weigh In On Danaher

A number of hedge funds have recently added to or reduced their stakes in DHR. GAMMA Investing LLC raised its holdings in Danaher by 22.2% in the 1st quarter. GAMMA Investing LLC now owns 9,126 shares of the conglomerate's stock worth $1,871,000 after acquiring an additional 1,660 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in Danaher by 4.0% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 207,169 shares of the conglomerate's stock worth $42,470,000 after acquiring an additional 7,907 shares during the last quarter. Ritholtz Wealth Management raised its holdings in Danaher by 8.8% in the 1st quarter. Ritholtz Wealth Management now owns 6,469 shares of the conglomerate's stock worth $1,326,000 after acquiring an additional 522 shares during the last quarter. Mission Wealth Management LP raised its holdings in Danaher by 0.7% in the 1st quarter. Mission Wealth Management LP now owns 13,096 shares of the conglomerate's stock worth $2,685,000 after acquiring an additional 96 shares during the last quarter. Finally, Sowell Financial Services LLC bought a new stake in Danaher in the 1st quarter worth approximately $1,442,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Teri List sold 2,778 shares of Danaher stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 11.20% of the company's stock.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher's dividend payout ratio (DPR) is presently 27.23%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.